Rx Product Updates (February 2017)

February 4th 2017

Read about the new Rx products featured in February 2017.

EUCRISAMARKETED BY:Anacor

INDICATION:The FDA has approved Anacor’s crisaborole ointment for the treatment of mild to moderate eczema in patients 2 years and older. Eucrisa is specifically indicated for the twice-daily treatment of atopic dermatitis.

DOSAGE FORM:Topical ointment: 2%

FOR MORE INFORMATION:anacor.com

SYNJARDY XRMARKETED BY:Boehringer Ingelheim and Eli Lilly

INDICATION:The FDA has approved Synjardy XR for the treatment of type 2 diabetes mellitus in adults. In combination with diet and exercise, the empagliflozin and metformin hydrochloride extended-release tablets are indicated to improve patients’ blood glucose level.

DOSAGE FORM:Tablets: 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, 25 mg/1000 mg

FOR MORE INFORMATION:synjardy.com

TRESIBAMARKETED BY:Novo Nordisk

INDICATION:The FDA has approved an expanded indication for Tresiba, the insulin degludec injection. The once-daily, long-acting basal insulin is now indicated for use in children as young as 1 year with type 1 or type 2 diabetes mellitus.

DOSAGE FORM:Injection: 100 U/mL and 200 U/mL

FOR MORE INFORMATION:tresiba.com

Related Content